Our results reaffirm the efficacy for IL2 as first line intralesional treatment in this patient population and present strong rational to further study the role of intralesional BCG as an adjunct to IL2 in patients with extensive local/regional recurrent melanoma, in-transit melanoma or distant cutaneous metastatic melanoma. Here, IL2 is linked to melanoma.